Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Hansol Lee

Citation

Annals of Oncology (2019) 30 (suppl_5): v760-v796. 10.1093/annonc/mdz268

Authors

H. Lee1, I.D. Silva2, M. Batten2, U. Palendira1, A. Ferguson1, M.S. Carlino3, A.M. Menzies4, R.P. Saw5, A.J. Spillane5, R.A. Scolyer6, G.V. Long7, J. Wilmott2

Author affiliations

  • 1 Medicine, University of Sydney, 2050 - Camperdown/AU
  • 2 Translational Research Group, Melanoma Institute Australia, 2065 - Sydney/AU
  • 3 Medical Oncology, The Crown Princess Mary Cancer Centre, 2145 - Westmead/AU
  • 4 Medical Oncology, Melanoma Institute Australia, University of Sydney, 2060 - North Sydney/AU
  • 5 Surgical Oncology, Melanoma Institute Australia, University of Sydney, 2060 - North Sydney/AU
  • 6 Pathology, Royal Prince Alfred Hospital, 2050 - Camperdown/AU
  • 7 Oncology, Melanoma Institute Australia, 2065 - Wollstonecraft/AU
More

Resources

Background

Anti-PD-1 and anti-CTLA-4 immunotherapies have become the standard of care for metastatic melanoma. However, the majority of patients develop resistance to therapy. Macrophages are abundant cells in tumours, but their role in immunotherapy response and resistance is largely unknown. This study investigated the role of macrophages in anti-PD-1 +/- CTLA-4 response in stage IV melanoma patients.

Methods

Transcriptomic and multiplex immunohistochemistry (mIHC) immune profiling were performed on formalin-fixed paraffin embedded tissue pre-treatment biopsies from advanced melanoma patients treated with anti-PD-1 (n = 19) or anti-PD-1 + anti-CTLA-4 (n = 10). Response and progression-free survival were assessed using RECIST criteria. Using tumour dissociates, mass cytometry was used to characterize macrophages in detail.

Results

Although there was no significant difference in CD68+ macrophages between responding and non-responding patients, responding patients had a significantly higher intratumoral density of CD14+ CD68+ CD16+ macrophages compared to non-responders at baseline (median= 192 versus 23; p = 0.006). Using mIHC, patients were classified into high/low CD16+ macrophages and differential RNA expression analysis was performed. CD16+ high macrophage tumours displayed increased expression of genes related to T cell activation (TIGIT, LAG3, ICOS, PDCD1, FASLG and TBX21), MHC class I presentation (TAP1, UBD, PSMB10 and B2M) and chemokine + cytokine activity (CXCL13, CXCL10, CXCL11, CXCL9, CXCR6 and CXCR3). Using mass cytometry, we determined that CD16+ macrophages are CD13+ HLA-DR+, ICOS+ CD86+/- LAG3- GITR- TIGIT-. Multivariate analysis showed that low LDH, low melanoma substage and the presence of high CD16+ macrophages were associated with a significantly better overall response rate (OR = 14; p = 0.011) and progression free survival (HR = 0.15; p = 0.016), but not overall survival (HR = 0.22; p = 0.068).

Conclusions

Presence of CD68+ CD14+ CD16+ macrophages in pre-treatment melanoma combined with low LDH and low melanoma substage strongly correlates with response and survival of advanced melanoma patients treated with immunotherapy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

James Wilmott.

Funding

National Health and Medical Research Council (NHMRC).

Disclosure

M.S. Carlino: Advisory / Consultancy: Amgen; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre. A.M. Menzies: Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. G.V. Long: Advisory / Consultancy: Amgen; Advisory / Consultancy: Array; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings